233 related articles for article (PubMed ID: 23372704)
1. Cysteine depletion causes oxidative stress and triggers outer membrane vesicle release by Neisseria meningitidis; implications for vaccine development.
van de Waterbeemd B; Zomer G; van den Ijssel J; van Keulen L; Eppink MH; van der Ley P; van der Pol LA
PLoS One; 2013; 8(1):e54314. PubMed ID: 23372704
[TBL] [Abstract][Full Text] [Related]
2. Sulfate depletion triggers overproduction of phospholipids and the release of outer membrane vesicles by Neisseria meningitidis.
Gerritzen MJH; Martens DE; Uittenbogaard JP; Wijffels RH; Stork M
Sci Rep; 2019 Mar; 9(1):4716. PubMed ID: 30886228
[TBL] [Abstract][Full Text] [Related]
3. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine.
Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X
mBio; 2019 Sep; 10(5):. PubMed ID: 31506309
[TBL] [Abstract][Full Text] [Related]
4. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process.
van de Waterbeemd B; Streefland M; van der Ley P; Zomer B; van Dijken H; Martens D; Wijffels R; van der Pol L
Vaccine; 2010 Jul; 28(30):4810-6. PubMed ID: 20483197
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.
Sanders H; Feavers IM
Expert Rev Vaccines; 2011 Mar; 10(3):323-34. PubMed ID: 21434800
[TBL] [Abstract][Full Text] [Related]
6. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them.
Holst J
Hum Vaccin; 2007; 3(6):290-4. PubMed ID: 17712231
[TBL] [Abstract][Full Text] [Related]
7. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
[TBL] [Abstract][Full Text] [Related]
8. Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strains.
Matthias KA; Reveille A; Connolly KL; Jerse AE; Gao YS; Bash MC
Vaccine; 2020 Feb; 38(10):2396-2405. PubMed ID: 32037226
[TBL] [Abstract][Full Text] [Related]
9. Outer membrane vesicles extracted from Neisseria meningitidis serogroup X for prevention of meningococcal disease in Africa.
Acevedo R; Zayas C; Norheim G; Fernández S; Cedré B; Aranguren Y; Cuello M; Rodriguez Y; González H; Mandiarote A; Pérez M; Hernández M; Hernández-Cedeño M; González D; Brorson SH; Rosenqvist E; Naess L; Tunheim G; Cardoso D; García L
Pharmacol Res; 2017 Jul; 121():194-201. PubMed ID: 28495657
[TBL] [Abstract][Full Text] [Related]
10. Re: Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease, Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Vaccine 2007;25(16):3080-4.
Lennon D
Vaccine; 2007 Sep; 25(39-40):6833; author reply 6833-4. PubMed ID: 17630051
[No Abstract] [Full Text] [Related]
11. Proteomic analysis of Neisseria lactamica and N eisseria meningitidis outer membrane vesicle vaccine antigens.
Vaughan TE; Skipp PJ; O'Connor CD; Hudson MJ; Vipond R; Elmore MJ; Gorringe AR
Vaccine; 2006 Jun; 24(25):5277-93. PubMed ID: 16682101
[TBL] [Abstract][Full Text] [Related]
12. Recent developments in vaccines to prevent meningococcal serogroup B infections.
Vermont CL; van den Dobbelsteen GP; de Groot R
Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
[TBL] [Abstract][Full Text] [Related]
13. Outer-membrane-vesicle vaccines: old but not forgotten.
Stephens DS
Lancet Infect Dis; 2011 Jun; 11(6):421-2. PubMed ID: 21489883
[No Abstract] [Full Text] [Related]
14. High dissolved oxygen tension triggers outer membrane vesicle formation by Neisseria meningitidis.
Gerritzen MJH; Maas RHW; van den Ijssel J; van Keulen L; Martens DE; Wijffels RH; Stork M
Microb Cell Fact; 2018 Oct; 17(1):157. PubMed ID: 30285743
[TBL] [Abstract][Full Text] [Related]
15. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks.
Taha MK; Zarantonelli ML; Alonso JM; Naess LM; Holst J; Feiring B; Rosenqvist E
Vaccine; 2007 Mar; 25(14):2537-8. PubMed ID: 16460845
[No Abstract] [Full Text] [Related]
16. Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.
Findlow J; Taylor S; Aase A; Horton R; Heyderman R; Southern J; Andrews N; Barchha R; Harrison E; Lowe A; Boxer E; Heaton C; Balmer P; Kaczmarski E; Oster P; Gorringe A; Borrow R; Miller E
Infect Immun; 2006 Aug; 74(8):4557-65. PubMed ID: 16861642
[TBL] [Abstract][Full Text] [Related]
17. Predicted vs observed effectiveness of outer membrane vesicle (OMV) vaccines against meningococcal serogroup B disease: Systematic review.
Harder T; Koch J; Wichmann O; Hellenbrand W
J Infect; 2017 Aug; 75(2):81-94. PubMed ID: 28487177
[TBL] [Abstract][Full Text] [Related]
18. Identification and optimization of critical process parameters for the production of NOMV vaccine against Neisseria meningitidis.
van de Waterbeemd B; Streefland M; van Keulen L; van den Ijssel J; de Haan A; Eppink MH; van der Pol LA
Vaccine; 2012 May; 30(24):3683-90. PubMed ID: 22464965
[TBL] [Abstract][Full Text] [Related]
19. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.
Nøkleby H; Aavitsland P; O'Hallahan J; Feiring B; Tilman S; Oster P
Vaccine; 2007 Apr; 25(16):3080-4. PubMed ID: 17287053
[TBL] [Abstract][Full Text] [Related]
20. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.
Bai X; Borrow R
Expert Rev Vaccines; 2010 Oct; 9(10):1203-17. PubMed ID: 20923270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
